Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501-Update on maintenance treatment, progression-free survival (PFS), and overall survival (OS).

被引：4

作者：

Aisner, J.

Manola, J.

Dakhil, S. R.

Stella, P. J.

Schiller, J. H.

机构：

[1] Canc Inst New Jersey, New Brunswick, NJ USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Wichita Community Clin Oncol Program, Wichita, KS USA

[4] St Joseph Mercy Hlth Syst, Ann Arbor, MI USA

[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.7560

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7560

引用

页数：1

共 50 条

[11] Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy
Karmali, R.
Fidler, M. J.
Cela, I.
Olmsted, G.
Rouhi, O.
Basu, S.
Walters, K. K.
Coon, J.
Bonomi, P.
Borgia, J. A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[12] Mature, real world progression-free survival (PFS) and overall survival (OS) milestones in stage IV, non-squamous, non-small cell lung cancer patients (nsqNSCLC) treated with first line pemetrexed(Pem)/platinum(Plat) followed by pem plus /- bevacizumab(Bev) maintenance.
Bhatt, Parva Kiran
Fughhi, Ibtihaj
Basu, Sanjib
Fidler, Mary J.
Borgia, Jeffrey Allen
Bonomi, Philip D.
Batus, Marta
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[13] Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05.
Velcheti, Vamsidhar
Castro, Michael
Watson, Drew
Kapoor, Shweta
Tyagi, Anuj
Sauban, Mohammed
Alam, Aftab
Roy, Kunal Ghosh
Rajagopalan, Swaminathan
Kulkarni, Shruthi
Mundkur, Nirjhar
Christie, Jim
Suseela, Rakhi Purushothaman
Ghosh, Adity
Basu, Kabya
Sahu, Diwyanshu
Ullal, Yashaswini
Nair, Prashant
Ahluwalia, Manmeet Singh
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[14] Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer
Socinski, Mark A.
Raju, Robert N.
Stinchcombe, Thomas
Kocs, Darren M.
Couch, Linda S.
Barrera, David
Rousey, Steven R.
Choksi, Janak K.
Jotte, Robert
Patt, Debra A.
Periman, Phillip O.
Schlossberg, Howard R.
Weissman, Charles H.
Wang, Yunfei
Asmar, Lina
Pritchard, Sharon
Bromund, Jane
Peng, Guangbin
Treat, Joseph
Obasaju, Coleman K.
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : 1963 - 1969
[15] PHASE II RANDOMIZED, OPEN-LABEL STUDY OF CETUXIMAB (CET) AND BEVACIZUMAB (BEV) IN COMBINATION WITH PACLITAXEL (P) AND CARBOPLATIN (C) IN PATIENTS WITH STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)
Bonomi, Philip
Mace, Joseph
Mandana, Romeo
Min, Myo
Mark, Olsen
Youssoufian, Hagop
Katz, Terry
Simms, Lorinda
Lee, Hyun Jung
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1292 - S1292
[16] Phase II study of sequence-dependent docetaxel (D)/vinorelbine (V) in patients (p) with advanced non-small cell lung cancer (NSCLC).
Sánchez, JM
Balañá, C
Font, A
Guillot, M
Manzano, J
Margelí, M
Sánchez, JJ
Aracil, C
Rosell, R
ANNALS OF ONCOLOGY, 2000, 11 : 122 - 122
[17] Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).
Camidge, D. R.
Bang, Y.
Kwak, E. L.
Shaw, A. T.
Iafrate, A. J.
Maki, R. G.
Solomon, B. J.
Ou, S. I.
Salgia, R.
Wilner, K. D.
Costa, D. B.
Shapiro, G.
LoRusso, P.
Stephenson, P.
Tang, Y.
Ruffner, K.
Clark, J. W.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[18] Final Progression-Free Survival (PFS), Updated Overall Survival (OS), And Safety Data from the Global, Randomized, Phase 3 Alex Study of Alectinib (ALC) Versus Crizotinib (CRZ) in Untreated Advanced ALK plus Non-Small Cell Lung Cancer (NSCLC)
Hoffknecht, Petra
Mok, Tony
Shaw, Alice I.
Camidge, D. Ross
Gadgeel, Shirish
Rosell, Rafael
Dziadziuszko, Rafal
Kim, Dong-Wan
Perol, Maurice
Ou, Sai-Hong
Bordogna, Walter
Smoljanovic, Vlatka
Hilton, Magalie
Peters, Solange
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 236 - 236
[19] PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
Patel, Jyoti D.
Socinski, Mark A.
Garon, Edward B.
Reynolds, Craig H.
Spigel, David R.
Olsen, Mark R.
Hermann, Robert C.
Jotte, Robert M.
Beck, Thaddeus
Richards, Donald A.
Guba, Susan C.
Liu, Jingyi
Frimodt-Moller, Bente
John, William J.
Obasaju, Coleman K.
Pennella, Eduardo J.
Bonomi, Philip
Govindan, Ramaswamy
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (34) : 4349 - U77
[20] Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.
Carcereny Costa, Enric
Taron, Miquel
Queralt, Cristina
de Aguirre, Itziar
Capdevila, Laia
Cros, Sara
Vergnenegre, Alain
De Marinis, Filippo
Massuti, Bartomeu
Reguart, Noemi
Ono, Mayumi
Buges, Cristina
Provencio, Mariano
Garrido Lopez, Pilar
Viteri Ramirez, Santiago
Gasco, Amaya
Miguel Sanchez, Jose
Cobo, Manuel
Drozdowskyj, Ana
Rosell, Rafael
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →